MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.13 (+0.24%)

Growth Price

Fairly valued

Stability Price

Overvalued by 63.00%

Company Metrics

  • P/E 33.99
  • P/S 3.89
  • P/B 3.5
  • EPS 1.63
  • Cash ROIC 12.97%
  • Cash Ratio 0.70
  • Dividend 1.84 / 3.29%
  • Avg. Vol. 8.73M
  • Shares 2.77B
  • Market Cap. 153.46B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Better Buy: Merck & Co. Inc. vs. AbbVie
Motley Fool - Jun 27, 2016
Among pharmaceutical companies, Merck & Co. (NYSE:MRK) and AbbVie (NYSE:ABBV) have been two of the most successful and profitable over the long run, and their share prices have posted impressive long-term returns for shareholders.
Merck & Co., Inc. (NYSE:MRK)Analyst Research Summary: - Zergwatch
BMO Capital Markets Reiterates Outperform Rating for Merck & Co., Inc. (MRK) - Community Financial News
Merck & Co., Inc. Keytruda Heads Deeper Into NSCLC
Business Finance News - Jun 27, 2016
Merck & Co Inc. (NYSE:MRK) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved KEYTRUDA (pembrolizumab), an anti-PD-1 therapy.
Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung ... - Benzinga
Merck gets CHMP Positive Opinion for KEYTRUDA for Advanced NSCLC - RTT News
Merck & Co. a Top 25 Dividend Giant With 3.33% Yield
Forbes - 19 hours ago
Merck & Co., Inc (NYSE: MRK) has been named as a Top 25 ”Dividend Giant” by ETF Channel, with a stunning $5.64B worth of stock held by ETFs, and above-average ”DividendRank” statistics including a strong 3.33% yield, according to the most recent ...
Is Merck & Co., Inc Januvia In Trouble? FDA Panel Decides Tomorrow
Bidness ETC - Jun 27, 2016
Jardiance will emerge as a particular threat to the alternate drug class of DPP4 inhibitors led by Merck & Co., Inc.'s (NYSE:MRK) Januvia/Janumet franchise after a label change. The drugs account for more than 15% of Merck's topline, bringing in annual ...
Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle
Motley Fool - Jun 16, 2016
Merck (NYSE:MRK) looks like it will win the race to have the first immunotherapy drug to gain Food and Drug Administration approval to treat newly diagnosed non-small cell lung cancer patients; but don't count rival Bristol-Myers Squibb (NYSE:BMY) out ...
Merck & Co., Inc. Keytruda One Step Ahead in Lung Cancer Portfolio - Business Finance News
Merck amp; Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results -
Merck & Co., Inc. (NYSE:MRK) & ACADIA Pharmaceuticals (NASDAQ:ACAD) Healthcare ...
Wall Street 24 - 19 hours ago
On Monday, Shares of Merck & Co., Inc. (NYSE:MRK) lost -1.02% to $55.31. The share price is trading in a range of $55.10 - $55.68.
HC Stocks Zone: Merck & Co., Inc. (NYSE:MRK), Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
Beatable Stocks in Active Notes- Merck & Co. (NYSE:MRK), QUALCOMM (NASDAQ:QCOM ... - Seneca Globe
Merck & Co. Inc. Stock Momentum Hits Strength
CML News - Jun 20, 2016
This is a momentum stock rating analysis for Merck & Co. Inc. (NYSE:MRK) . The company has a four bull momentum rating which indicates some strength.
Is it Finally Safe to Buy Merck & Co Inc (NYSE:MRK)?
Street Report - Jun 23, 2016
Merck & Co Inc (NYSE:MRK) stock is currently trading 5.04% below its 52-week-high, 24.84% above its 52-week-low. The 1-year stock price history is in the range of $45.69 - $60.07.
Reliable stocks in today's share market: Merck & Co. Inc. (NYSE:MRK) - The News Journal
HC Stocks Newsbeat: Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) - share market updates (press release)
Can Merck & Co., Inc. (NYSE:MRK)'s Gardasil Trigger More HPV Vaccine Coverage?
Market Exclusive - Jun 22, 2016
A study has revealed that Merck & Co., Inc. (NYSE:MRK)'s Gardasil significantly reduced HPV infections in countries where it has been adopted as a vaccine against the virus.
Merck & Company Inc. (new) (MRK) Closes 1.02% Down on the Day for June 27 - Jun 27, 2016
Dow Jones component Merck & Company Inc. (new) (MRK) saw its stock move -1.02% to $55.31, representing a per-share move of $0.57, on volume of 13.09 million shares for Monday.